{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:58:44Z","timestamp":1770677924231,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,4]]},"DOI":"10.7759\/cureus.63841","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:10:16Z","timestamp":1720105816000},"source":"Crossref","is-referenced-by-count":1,"title":["The Evolving Role of Chlorthalidone and Hydrochlorothiazide as First-Line Treatments for Hypertensive Patients"],"prefix":"10.7759","author":[{"given":"Alan D","family":"Kaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah  C","family":"Corley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter  P","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan  T","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa  E","family":"Neuchat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew  J","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Willett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018, 71:1269-324. 10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"ref2","unstructured":"Hypertension Cascade. Hypertension Prevalence, Treatment and Control Estimates Among U.S. Adults Aged 18 Years and Older Applying the Criteria from the American College of Cardiology and American Heart Association\u2019s 2017 Hypertension Guideline\u2014NHANES 2015-2018. (2017). https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence_2018.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.191106","article-title":"Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses","volume":"59","author":"Roush GC","year":"2012","unstructured":"Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012, 59:1110-7. 10.1161\/HYPERTENSIONAHA.112.191106","journal-title":"Hypertension"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","article-title":"Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis","volume":"57","author":"Dorsch MP","year":"2011","unstructured":"Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011, 57:689-94. 10.1161\/HYPERTENSIONAHA.110.161505","journal-title":"Hypertension"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events","volume":"387","author":"Ishani A","year":"2022","unstructured":"Ishani A, Cushman WC, Leatherman SM, et al.. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022, 387:2401-10. 10.1056\/NEJMoa2212270","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.7454","article-title":"Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension","volume":"180","author":"Hripcsak G","year":"2020","unstructured":"Hripcsak G, Suchard MA, Shea S, et al.. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020, 180:542-51. 10.1001\/jamainternmed.2019.7454","journal-title":"JAMA Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23365","article-title":"Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function","volume":"4","author":"Edwards C","year":"2021","unstructured":"Edwards C, Hundemer GL, Petrcich W, et al.. Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function. JAMA Netw Open. 2021, 4:e2123365. 10.1001\/jamanetworkopen.2021.23365","journal-title":"JAMA Netw Open"},{"key":"ref8","article-title":"Hydrochlorothiazide","author":"Herman LL","year":"2021","unstructured":"Herman LL, Bashir K. Hydrochlorothiazide. StatPearls. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0000000000000486","article-title":"Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients","volume":"26","author":"Dineva S","year":"2021","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T. Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients. Blood Press Monit. 2021, 26:160-8. 10.1097\/MBP.0000000000000486","journal-title":"Blood Press Monit"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-013-0372-1","article-title":"Chlorthalidone: mechanisms of action and effect on cardiovascular events","volume":"15","author":"Roush GC","year":"2013","unstructured":"Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep. 2013, 15:514-21. 10.1007\/s11906-013-0372-1","journal-title":"Curr Hypertens Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie X","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al.. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016, 67:728-41. 10.1053\/j.ajkd.2015.10.011","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61343-9","article-title":"Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial","volume":"381","author":"Weber MA","year":"2013","unstructured":"Weber MA, Jamerson K, Bakris GL, et al.. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013, 381:537-45. 10.1016\/S0140-6736(12)61343-9","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f B","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al.. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005, 366:895-906. 10.1016\/S0140-6736(05)67185-1","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li EC","year":"2014","unstructured":"Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014, 2014:CD009096. 10.1002\/14651858.CD009096.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan N","year":"2006","unstructured":"Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006, 174:1737-42. 10.1503\/cmaj.060110","journal-title":"CMAJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey RM","year":"2022","unstructured":"Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022, 328:1849-61. 10.1001\/jama.2022.19590","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001777","article-title":"Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis","volume":"36","author":"Thomopoulos C","year":"2018","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018, 36:1637-47. 10.1097\/HJH.0000000000001777","journal-title":"J Hypertens"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub2","article-title":"Beta-blockers for hypertension","author":"Wiysonge CS","year":"2007","unstructured":"Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007, CD002003. 10.1002\/14651858.CD002003.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto T","year":"2004","unstructured":"Morimoto T, Gandhi TK, Fiskio JM, et al.. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004, 10:499-509. 10.1111\/j.1365-2753.2003.00484.x","journal-title":"J Eval Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen R","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, et al.. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021, 78:591-603. 10.1161\/HYPERTENSIONAHA.120.16667","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.5.643","article-title":"Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it","volume":"5","author":"Beltrami L","year":"2006","unstructured":"Beltrami L, Zingale LC, Carugo S, Cicardi M. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf. 2006, 5:643-9. 10.1517\/14740338.5.5.643","journal-title":"Expert Opin Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198710001-00023","article-title":"Microvascular mechanisms involved in calcium antagonist edema formation","volume":"10","author":"Gustafsson D","year":"1987","unstructured":"Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987, 10:S121-31. 10.1097\/00005344-198710001-00023","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.35.5.1025","article-title":"Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program","volume":"35","author":"Franse LV","year":"2000","unstructured":"Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000, 35:1025-30. 10.1161\/01.hyp.35.5.1025","journal-title":"Hypertension"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators","volume":"131","author":"Kostis JB","year":"1996","unstructured":"Kostis JB, Shelton B, Gosselin G, et al.. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators.  Am Heart J. 1996, 131:350-5. 10.1016\/s0002-8703(96)90365-8","journal-title":"Am Heart J"},{"key":"ref25","article-title":"Calcium channel blockers","author":"McKeever RG","year":"2023","unstructured":"McKeever RG, Hamilton RJ. Calcium channel blockers. StatPearls. StatPearls Publishing , Treasure Island, FL; 2023."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.06.031","article-title":"Risk of thiazide-induced hyponatremia in patients with hypertension","volume":"124","author":"Leung AA","year":"2011","unstructured":"Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011, 124:1064-72. 10.1016\/j.amjmed.2011.06.031","journal-title":"Am J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6730.975","article-title":"Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects","volume":"300","author":"Carlsen JE","year":"1990","unstructured":"Carlsen JE, K\u00f8ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990, 300:975-8. 10.1136\/bmj.300.6730.975","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13396","article-title":"Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients","volume":"15","author":"Chekka LM","year":"2022","unstructured":"Chekka LM, Cooper-DeHoff RM, Gums JG, Chapman AB, Johnson JA. Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. Clin Transl Sci. 2022, 15:2858-67. 10.1111\/cts.13396","journal-title":"Clin Transl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241324-the-evolving-role-of-chlorthalidone-and-hydrochlorothiazide-as-first-line-treatments-for-hypertensive-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:10:21Z","timestamp":1720105821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241324-the-evolving-role-of-chlorthalidone-and-hydrochlorothiazide-as-first-line-treatments-for-hypertensive-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.63841","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}